

## Global BD



### Jørund Sollid, PhD

Global Lead, Neuroscience & Immuno-Inflammation BD  
Mobile: +33 765 76 66 59 / [jorund.sollid@servier.com](mailto:jorund.sollid@servier.com)

## R&D External Innovation



### Isabelle Dupin-Roger, PharmD

Director of External Innovation, Neuroscience & Immuno-Inflammation R&D  
Mobile: +33 6 87 25 03 73 / [isabelle.dupin-roger@servier.com](mailto:isabelle.dupin-roger@servier.com)

## Local BD



### USA

#### Pat Fetaya, MBA, MSc

Head, US Business Development, Servier Pharmaceuticals, USA  
Mobile: +1.609.285.8275 / [pat.fetaya@servier.com](mailto:pat.fetaya@servier.com)



### Asia

#### Cynthia Wang, MBA, MSc

Director, Director, Global Business Development, Asia-Pacific region  
Mobile: +86 13910100149 / [cynthia.wang@servier.com](mailto:cynthia.wang@servier.com)

## Global BD Coordination



### Bénédicte Barrault

GBD Coordination Officer, Neuroscience & Immuno-Inflammation  
[benedicte.barrault@servier.com](mailto:benedicte.barrault@servier.com)

## Active Partnerships



## Partnering interests

# Neuroscience

### Discovery, pre-clinical and early clinical stage

#### Biological mechanisms

Normalising disease-disrupted protein homeostasis

- Clearance of toxic proteins (Autophagic-Lysosomal Network ); Targeted degradation (AUTAC, PROTAC, LYTAC)
- Regulation of transcription and translation of targets

#### Target class

Targeting RNA/ proteins genetically and causally linked to disease

#### Indications : Targeting sub-populations and rare forms of neurodegenerative disease

- Multiple System Atrophy
- Familial Amyotrophic Lateral Sclerosis
- Hereditary forms of Parkinson Disease
- Spinocerebellar Ataxia
- Progressive Supranuclear Palsy

#### Modalities

- Small molecules
- Targeted Protein Degradation
- Oligonucleotides, ASO

#### Drug delivery

- Central administration with a medical device
- Systemic administration for CNS RNA technologies
- Brain distribution and targeted delivery (formulation)
- Technologies to improve the efficacy/specificity of cellular delivery (ASO)

## Partnering with Servier

Partnership is embedded in our culture with highly engaged and diverse teams partnering for a shared purpose - contributing to therapeutic progress to serve patient needs. Our partnership approach serves one goal: to bring life-changing treatments to patients faster. We strive to always put patients first, leading to better outcomes for ourselves and our partners.



## A partner of choice

### A partner with strong commitment

Servier is an independent pharmaceutical company committed to therapeutic progress to serve patient needs. Its unique governance allows Servier to reinvest all its profits to support its development, as well as plan and invest with a long-term view, in line with its vocation. Servier long-term vision applies to its partnership philosophy.

### A partner with a global presence

With €4.7Bn of revenue in 2021 across 150 countries worldwide, the Group has a growing presence in the USA and Japan, a strong EU presence and a deep knowledge of emerging countries and China.

### A partner with proven expertise and experience

Servier is very focused on specialty care oncology with a proven expertise of over 60 years in cardiovascular and metabolic diseases. It is developing new therapeutic solutions to serve unmet patient needs. From R&D to commercialization, we have proven experience to help new therapeutic innovations become reality for patients, alone or with partners.

### A partner you can rely on

Servier is proud of what has been achieved with its partners so far. Servier has a strong track record of providing flexible partnership structures to its many partners, as well as an R&D infrastructure with 2,900 people in France, Hungary and Boston and an extensive commercial knowledge of global markets.

## Partnering interests



### Oncology

#### Discovery & Early Clinical Focus

##### Cancer cell Targeting

- Synthetic lethality
- Apoptosis
- Precision oncology
- Epigenetic regulators

##### Immuno-oncology

- Tumor micro-environment
- T cell targeting

#### Modalities

- Small molecules and biologics (mAbs/bispecifics, ADCs)

#### Late-stage Clinical Focus

- Hematologic tumors (NHL, ALL, AML)
- Solid tumors; GI as a priority



### Immuno-inflammation

#### Inflammatory & autoimmune disease

- Primary Sjögren syndrome
- Autoimmune diseases
- And other diseases sharing similar pathophysiological mechanisms

#### Modalities

- Small molecules
- mAb/bispecifics



### Neuroscience

- Multiple System Atrophy
- Familial Amyotrophic lateral sclerosis
- Hereditary forms of Parkinson's Disease
- Spinocerebellar Ataxia
- Progressive Supranuclear Palsy

#### Modalities

- Small molecules
- ASO
- Targeted Protein Degradation



### Cardiovascular & Metabolism diseases

Acquire or license market-ready or mature assets for some geographies